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ABSTRACT
Objectives To examine the “Scottish effect”—namely, the
growing divergence between mortality in Scotland and
England that is not explained by national differences in
levels of deprivation—and, more specifically, to examine
the extent to which the Scottish effect is explained by
cross national differences in the prevalence of problem
drug use.
Design Secondary analysis of cohort study (the DORIS
study).
Participants 1033 Scottish drug users recruited to the
cohort study in 33 drug treatment facilities across
Scotland in 2001-2 and followed up 33 months later in
2004-5.
Results 38 deaths occurred in the cohort, giving a
standardised mortality ratio for the cohort of 1244 (95%
credible interval 876 to 1678). Only 22 of the 38 deaths in
drug users were classified as drug related deaths. From
estimates of the size of the problem drug using
populations in both England and Scotland, the
contribution of deaths in drug users to national death
rates can be estimated: the attributable risk fraction for
Scotland is 17.3% (12.3% to 22.8%) and that for England
is 11.1% (7.8% to 14.8%). Excluding estimated numbers
of deaths in drug users would bring down age
standardised mortality at ages 15-54 years from 196 to
162 per 100000 in Scotland and from 138 to 122 per
100000 in England; 32.0% (22.3% to 43.0%) of the
excess mortality in Scotland is due to drug use.
ConclusionAlthoughproblemdruguse isa lowprevalence
riskbehaviour, it carriesahighmortality; thestandardised
mortality ratio for Scottish drug users is 12 times as high
as for the general population. The higher prevalence of
problemdruguse inScotland than in Englandaccounts for
a third of Scotland’s excess mortality over England.
Successful public health efforts to reduce the prevalence
of problemdrug use in Scotlandor deaths in Scottish drug
userswouldhave adramatic impact onoverallmortality in
Scotland.
INTRODUCTION
Death rates are known to be higher in Scotland than in
England andWales. In recent years, although Scottish
death rates have been falling, the relative difference
between the nations has increased: mortality was 12%
higher in Scotland than in England andWales in 1981
but 15% higher in 2001.1 In the past, poorer health in
Scotland has been attributed to higher levels of
deprivation: if local mortality was adjusted for local
Carstairs deprivation scores (based on levels of adult
male employment, car ownership, social class compo-
sition, and overcrowding), 60% of Scotland’s excess
mortality in 1981 was explained by greater relative
deprivation.2 However, by the 1991 census (and
continuing at the 2001 census) deprivation was
accounting for less than half of Scotland’s excess
mortality,1 3 and the unaccounted for excess was
increasingly marked among the Scottish male popula-
tion aged 0-44 years.1 This growing disproportionality
has been dubbed the “Scottish effect.”
Possible explanations for the Scottish effect reflect
thewider debates that have taken place on the causes of
inequalities in health in theUnitedKingdomever since
the publication of the Black report in 1980.4 Thus,
people have suggested that the effect is a measurement
artefact, that Carstairs deprivation scores capture
relative deprivation less effectively in the 21st century
than they did in 1981. Hanlon and colleagues discount
the artefact explanation and, pointing to higher levels
of alcohol consumption, lower levels of physical
activity, and a higher prevalence of smoking in
Scotland (comparedwith England), tentatively suggest
that “Scots in an equivalent deprivation category have
higher levels of personal risk factors.”1 Our purpose
here is to endorse that suggestion and posit that a single
risk factor—problemdruguse—maybe responsible for
a large part of the observed, deprivation adjusted, cross
national differences in rates of premature death.
METHODS
Numbers and trends in “drug related deaths” in
Scotland are regularly reported,5 but the definition of
drug related deaths used in these reports is deliberately
andproperly a restrictiveone, limited todeathsdirectly
due to the pharmacological effect of an illicit drug.6 In
order to estimate the numbers of deaths in a population
of drug users, deaths that embrace not just overdoses
from illicit drugs but also deaths from bloodborne
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infections, from violent assaults, from suicides, and
from other events associated with drug use, cohort
studies on populations of drug users are needed.7 8
DORIS (drug outcomes research in Scotland) is the
largest ever repeat interview study of Scottish drug
users, involving following up 1033 problemdrug users
who started a new treatment episode in 33 drug
treatment agencies (representing a range of treatment
modalities and including treatment in prisons) across
Scotland in 2001-2. Of the 1180 problem drug users
who were asked to participate, 147 people refused,
giving a participation rate of 87.5%; the most common
reason given for refusal was lack of time. The DORIS
sample comprises one in 11 of the drug users entering
treatment in 2001 and returned in the Scottish drug
misuse database (a database of all new entrants into
drug treatment facilities), and the sociodemographic
profile of the sample is comparable to the profile of
returns made to that database in 2001.9 DORIS
respondents had a mean age of 28, and 69% of
respondents were male; although misuse of several
drugs was the common pattern, the great majority of
respondents reported that their main drug was heroin.
We matched data between General Register Office
for Scotland (GROS) mortality data and those mem-
bersof theDORIS samplewhowere lost to follow-upat
33 months. The Vital Events Branch of GROS then
established which of the deaths in the DORIS cohort
hadpreviously been classified as a drug relateddeath in
earlier annual reports.5Wealsomade inquirieswith the
Office forNational Statistics in England about whether
the death of aDORIS samplememberwho had died in
England had been included in their equivalent count of
drug related deaths.
Estimates can be made of the total number of deaths
in drug users (as opposed to drug related deaths) by
combining the standardised mortality ratio from the
DORIS cohort with prevalence data on problem drug
use (available for both Scotland and England),10 11
calculated by using population estimation methods.
These methods (identical for both the Scottish and the
English prevalence estimates) model the “hidden
population” of problem drug users not in contact
with services from overlaps between populations of
drug users known to a range of different services,
including the drug treatment services where the
DORIS sample was recruited. Therefore, any possible
numerator-denominatorbias shouldbequite limited in
extent and estimates of death will include deaths of
hidden drug users as well as of those in contact with
services. The contribution of deaths among drug users
to overall Scottish and English death rates can be
calculated as the attributable risk fraction (ARF) in the
formula ARF=Ppdu(SMR/100−1)/(Ppdu(SMR/100−1)
+1), where Ppdu is the proportion of the population
who are problem drug users and SMR is the
standardised mortality ratio for that same subpopula-
tion calculated through indirect standardisation to the
Scottish population.12
Detailed age and sex breakdowns are not publicly
available for the English problem drug user cohort
study that is the equivalent of DORIS (the national
treatment outcomes research study, NTORS), so we
have used the standardised mortality ratios for the
DORIS cohort to calculate both the English and the
Scottish attributable risk fractions. This seems to be
acceptable, as the overall DORIS and NTORS death
rates are nearly identical and the NTORS data were
gathered at an earlier period (1995-9) than DORIS
(2001-4). We calculated standardised mortality rates
for England and Scotland by direct standardisation to
the European standard population. We estimated the
standardised mortality for the non-drug using popula-
tion in the two countries and, comparing these rates
with theobserved rates, estimated theproportionof the
excess mortality in Scotland that was attributable to
drug use. Mortality data and population data came
from the Office for National Statistics and the General
Register Office (Scotland).13-15
We report posterior means and 95% credible inter-
vals estimated withWinBUGS,16 based on two parallel
chains of length 10 000 following a burn-in of 10 000.
Thecredible intervals are rangesofvalueswithinwhich
the relevant parameter lieswith aprobability of 0.95; in
this sense, theymay be interpreted in a similar manner
to confidence intervals. The relevant WinBUGS code
can be found on Leyland’s website (www.sphsu.mrc.
ac.uk/research_project.php?prjid=BUGSCODE&b
crumbs=MH.METH).
RESULTS
Deaths in DORIS cohort
Thirty eight deaths occurred in the 1033 DORIS
samplemembers in the 33monthperiod, ofwhichonly
just over half (22) were classified by the General
Register Office for Scotland/Office for National
Statistics as “drug related deaths.” The cause of death
of one cohort member remained unascertained,
despite further inquiries by the General Register
Office. Of the remaining 15 cohort deaths that were
not classed as drug related, six were suicides, including
three overdoses (of paracetamol, amitriptyline, and
colchicine), one was an overdose of “undetermined
intent” involving fluoxetine and propranolol, three
Table 1 | Crude death rates in DORIS sample
Person
years
All
deaths
Drug related
deaths cohort
Crude death rate (95% CI)
per 1000 person years
Crude death rate (95% CI)
for drug related deaths cohort
Men 1953 27 15 14 (9 to 20) 7 (4 to 13)
Women 864 11 7 13 (6 to 23) 8 (3 to 17)
Total 2817 38 22 13 (10 to 18) 8 (5 to 12)
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were due to an “infection associated with drug abuse”
(with a fourth due to endocarditis), two were due to
assaults, one was due to “alcoholic liver disease,” and
one was due to hypothermia/exposure.
Themortality in theDORIS sample is comparable to
rates in other cohort studies of drug users in England
(the NTORS cohort) and abroad.7 8 Table 1 shows
mortality as a crude death rate per 1000 person years,
where person years are calculated as the difference
between the dates of death and of the initial DORIS
interview.
Possible contribution of drug use to Scottish excess
mortality
The standardisedmortality ratio formen in theDORIS
cohort (whose age at recruitment ranged from16 to 53,
with a mean age of 28) was 834 (95% credible interval
549 to 1182) (table 2). In 2002 the age standardised
mortality for Scottish men aged 15-54 was 259 per
100 000, and for England it was 173 per 100 000. For
the same age group, the prevalence of problem drug
use in Scotland in 2003 was 2.69% (95% confidence
interval 2.11% to 4.17%). 10 In England in 2004-5 the
prevalence of problemdrug use amongmen aged 15 to
64 was 1.32%.11 Assuming that opiate use among men
aged 55 to 64 was negligible, this equates to a
prevalence of 1.65% among men aged 15 to 54.
These data led to an estimated attributable risk fraction
of all deaths among male drug users in Scotland of
16.3% (95% credible interval 8.8% to 25.5%) and an
attributable risk fraction in England of 10.7% (6.8% to
15.1%). If the estimated deaths in drug users in the two
male populations was excluded, the standardised
mortality in the two populations would fall from 259
per 100 000 to 217 (95% credible interval 192 to 238)
per 100 000 in Scotland and from 173 per 100 000 to
154 (146 to 161) per 100 000 for England. This
indicates that 27.5% (95% credible interval 9.3% to
50.3%) of the excessmortality for Scottishmen aged 15
to 54 is due to the greater prevalence of problem drug
use in Scotland.
The overall (in men and women) standardised
mortality ratio for the DORIS cohort is 1244 (95%
credible interval 876 to 1678), and the overall
attributable risk fraction is 17.3% (12.3% to 22.8%)
for Scotland and 11.1% (7.8% to 14.8%) for England.
The corresponding prevalences of problem drug use
are1.84% (95%confidence interval 1.84% to2.01%) for
Scotland and 1.07% (1.06% to 1.11%) for England.
Exclusionof the estimateddeaths indrugusers resulted
in falls in the standardised mortality from 196 per
100 000 to 162 (95% credible interval 150 to 173) per
100 000 in Scotland and from 138 per 100 000 to 122
(117 to 127) per 100 000 in England. This suggests that
32.0% (95% credible interval 22.3% to 43.0%) of the
excess Scottish mortality is due to the greater
prevalence of problem drug use in Scotland.
DISCUSSION
Our data suggest that one particular risk behaviour,
problem drug use, accounts for a third of excess
mortality in Scotland compared with England among
people aged 15 to 54, supporting Hanlon and
colleagues’ suggestion that the “Scottish effect” can
be explained by higher prevalences of risk behaviours
in Scotland than in England within a particular level of
deprivation. Note also that a rapid increase in problem
drug use (and particularly heroin use) occurred in the
1980s in Scotland,17 at the very point at which
deprivation measures (Carstairs deprivation scores)
began to account for less than half of the cross national
variance in rates.
Uncertainties and limitations
Uncertainty intervals are attached to these various
estimates. For Scottish men aged 15-54 (for whom the
“Scottish effect” is strongest), deaths indrugusers could
be accounting for asmuch as half or as little as a tenth of
the excess Scottish mortality; however, intervals are
Table 2 | Proportion of problemdrug users, standardisedmortality ratios, attributable risk fractions, age standardisedmortality,
excessmortality, and proportion of excess due to drug use (with 95%credible intervals unless stated otherwise) in Englandand
Scotland, formen and formen andwomen combined
Men Men and women
England Scotland England Scotland
Proportion (%) of problem drug users
(95% confidence interval)
1.65* 2.69 (2.11 to 4.17) 1.07 (1.06 to 1.11) 1.84 (1.84 to 2.01)
Standardisedmortality ratio inpopulation
of drug users (DORIS cohort)
† 834 (549 to 1182) † 1244 (876 to 1678)
Attributable risk fraction (%) 10.7 (6.8 to 15.1) 16.3 (8.8 to 25.5) 11.1 (7.8 to 14.8) 17.3 (12.3 to 22.8)
Age standardised mortality per 100 000 173 (170 to 175) 259 (250 to 267) 138 (136 to 139) 196 (191 to 201)
Excess mortality per 100 000 – 86 (77 to 95) – 58 (53 to 64)
Age standardised mortality per 100 000,
excluding deaths in drug users
154 (146 to 161) 217 (192 to 238) 122 (117 to 127) 162 (150 to 173)
Excess mortality per 100 000, excluding
deaths in drug users
– 63 (42 to 80) – 40 (32 to 47)
Proportion of excessmortality due to drug
use (%)
– 27.5 (9.3 to 50.3) – 32.0 (22.3 to 43.0)
*95% confidence interval not given.
†Assumed to be same as for DORIS cohort.
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narrower when deaths in men and women are
combined. The time periods of the different datasets
used are not wholly matched; although we have been
able to use datasets from contiguous time periods,
readers must decide on the windows of applicability of
the different datasets.
The definitions of drug users used in the DORIS
study and the two different prevalence estimates differ
slightly: eligibility in the DORIS study was simply a
matter of starting a new episode of drug treatment; in
theEnglish prevalence study the estimate related to use
of opiates, crack/cocaine, or both; in the Scottish
prevalence study the estimate related to use of opiates,
benzodiazepines, or both. Such differences in defini-
tion raise the possibility of numerator-denominator
biases in mortality calculations, but the practical
importance of definitional differences in this instance
is small—for example, although the DORIS sample
might have started treatment because of misuse of a
range of different substances other than opiates or
benzodiazepines, in fact 88% of the sample had used
heroin in the three months before recruitment.
The formula used to calculate the attributable risk
fraction has been judged to be suitable when no
confounding of the exposure-disease association
exists,18 but we cannot explore the possibility of such
confounding in these data. The mortality in DORIS is
consistent with that found in studies elsewhere,7 12 and
the DORIS sample is the largest repeat interview
cohort study of Scottish drug users. Thus, although the
sample represents less than a tenthof the annual total of
people seeking treatment for drug use in Scotland, our
claim that mortality in the DORIS sample indicates
that deaths in drug users represent an important
fraction of deaths in the Scottish 15-54 year old
population is warranted. However, a larger follow-up
study of drug users would provide more certain
estimates of mortality in drug users.
Implications
Problem drug use is a low prevalence risk behaviour
compared with tobacco consumption, high alcohol
consumption, and low levels of physical activity, but it
carries a high mortality: mortality in the DORIS
sample was 12 times that of the general Scottish
population aged 15 to 54. This high mortality is not
fully reflected in published reports on “drug related
deaths,” as definition of such deaths is deliberately and
properly a restrictive one, limited to overdoses from
illicit drugs and not the wider spectrum of deaths
(including deaths from infections, assaults, and over-
dose from drugs such as paracetamol) found in the
DORIS sample. In the DORIS sample, only just over
half the deaths that occurred among drug users were
classed as drug related deaths. It follows that deaths in
problem drug users are a potentially important
contributor to national and local mortality.19 20
Explorations of health inequalities, reflected in
differential mortality, thus need to embrace studies of
differences in the prevalence of problem drug use. The
identificationof an important role forproblemdruguse
in understanding excess mortality does not, of course,
decrease the importance of the link between socio-
economic deprivation and poor health, as the associa-
tionbetween relativedeprivationanduptakeofdrugs is
long established.6 21 22
Successful public health initiatives to reduce the
prevalence of problem drug use or to reduce deaths
among drug users would have a strong impact on
overall mortality in both Scotland and England. Policy
efforts to reduce health inequalities could and should
makedrugmisuse a prime target, and theneed to tackle
drug misuse as part of a strategy to reduce health
inequalities was recognised in the report of the
Ministerial Task Force on Health Inequalities pub-
lished on 19 June this year23. The evidence is mixed on
how successful current public health initiatives have
been in Scotland. No trend data on deaths in Scottish
drugusers are available, but that fractionof suchdeaths
that are classed as drug related deaths has continued to
rise.24 However, the latest Scottish prevalence esti-
mates show a small fall in the prevalence of problem
drug use between 2000 and 2003.10
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